logo
Plus   Neg
Share
Email

Merck Announces New Phase III Data For Suvorexant - Quick Facts

Merck & Co. Inc. (MRK) announced the new Phase III Data for suvorexant, the investigational medicine the compoany is developing for the treatment of insomnia.

The 12-month study was designed to assess the safety of suvorexant, while also evaluating its longer term efficacy. The company said it presented new results from a two-month discontinuation phase that followed the 12-month study at the 21st Congress of the European Sleep Research Society or ESRS.

The company said that the results from the two-month discontinuation phase showed that, after daily use of a consistent dose of suvorexant for one year, patients who stopped taking the medicine experienced a return of their sleeping difficulties to levels similar to those reported by patients who received placebo over the course of the trial.

The company noted that Patients who continued to receive suvorexant for the additional two months experienced mean improvements in their ability to fall asleep and stay asleep that were consistent with those seen over the first 12 months compared to placebo. Adverse experiences reported in the two-month discontinuation phase were generally consistent with those reported during the 12-month study.

The company stated that it plans to file a New Drug Application (NDA) for suvorexant with the U.S. Food and Drug Administration or FDA in 2012. If approved, suvorexant would be the first in a new class of medicines, called orexin receptor antagonists, for use in patients with difficulty falling or staying asleep. The company said it anticipates that suvorexant will be evaluated by the Controlled Substance Staff of the FDA.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
In a move likely to escalate the trade dispute between the U.S. and China, President Donald Trump has threatened to impose new tariffs on $200 billion worth of Chinese goods. Trump said in a statement Monday evening he has directed U.S. Trade Representative Robert Lighthizer to identify $200 billion... UBS Group AG Chief Executive Officer Sergio Ermotti said blockchain technology is almost a must for business. In an interview with CNBC, the head of the Swiss banking giant said he believes the technology is definitely an opportunity in the long term. According to him, the technology will help companies free up resources, and blockchain in particular is a great way to increase those efficiencies. In the age of social media, it takes mere hours for a company to suffer the backlash of of allegations of racism. For some companies, these incidents have hurt their bottom line and sullied their reputations. For others, they were a blip caused by clumsy if not altogether coincidental missteps. In...
Follow RTT